NCT01785433View on ClinicalTrials.gov

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions

COPD

Interventions

DRUG

Tiotropium HFA BAI 4.5 mcg

DRUG

Tiotropium HFA BAI 9.0 mcg

DRUG

SPIRIVA® HandiHaler® 18 mcg/day

DRUG

Spiriva® Respimat® 5 mcg/day

Trial Locations (5)

Unknown

Teva Investigational Site 32170, Berlin

Teva Investigational Site 32169, Gauting

Teva Investigational Site 32171, Großhansdorf

Teva Investigational Site 32167, Mannheim

Teva Investigational Site 32168, Wiesbaden

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01785433 - To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter